Invitrogen Introduces New Patent-Protected E-Gel Product.Company named to new patent index; recognized for value of its intellectual property CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN), a global leader in life sciences, today announced the availability of E-Gel([R]) CloneWell[TM] SYBR SYBR Synergy Brands, Inc. (stock symbol) ([R]) gels, the newest addition to the company's patented E-Gel[R] line of products. These gels provide a fast and convenient way to obtain improved cloning efficiency without exposing the user to harmful UV trans-illumination. Users of these new products can avoid gel slicing and UV exposure, leading to a safer and more efficient DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. recovery method. The DNA is stained with non-toxic, non-mutagenic SYBR[R] Safe stain, which is visualized with the Safe Imager[TM] device to deliver DNA free of strand breaks and mutations, resulting in higher cloning efficiencies. The E-Gel[R] CloneWell[TM] SYBR([R]) Safe gels are the latest Invitrogen products to be launched that are protected by a U.S. patent. The company holds more than 800 patents on key technologies that accelerate research and scientific discovery. The patents span the spectrum from molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller to stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young . In October, Invitrogen was named as an inaugural constituent of the Ocean Tomo 300 Patent Index, the first equity index based on the value of corporate intellectual property. The Index is priced and published by the American Stock Exchange American Stock Exchange (AMEX) Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. and is a diversified, market-weighted index of companies that own the most valuable patents relative to their book value. The Index is the first major, broad-based market equity index to be launched in 35 years. Its purpose is to provide a tool for identifying and valuing innovation and intellectual capital. "Invitrogen is very pleased to be included as an inaugural member of the Ocean Tomo 300 Index," said Greg Lucier, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Invitrogen. "Innovation is the cornerstone of our business and we take great pride in how our scientific breakthroughs can accelerate research and development that will one day lead to lifesaving therapies." The company has vigorously defended its patents against any type of infringement. Last month the U.S. District Court for the Western District of Texas entered a favorable decision to Invitrogen in their ongoing patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. lawsuit against Stratagene, Inc. Invitrogen was awarded more than $16 million in damages for Stratagene's infringement of its competent cell patent. The court also entered an injunction against further infringement by Stratagene. About Invitrogen Corporation Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics Noun 1. functional genomics - the branch of genomics that determines the biological function of the genes and their products genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) , proteomics, bioinformatics and cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to, users of these new gels can expect improved cloning efficiency. Potential risks and uncertainties include, but are not limited to, the risks that: the improved cloning efficiency generated by Invitrogen's E-Gel([R]) CloneWell[TM] SYBR([R]) gels will not be higher than other products or that the improved cloning efficiency will not meet customer expectations, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion